Alvotech (ALVO) Cash from Investing Activities (2022 - 2026)
Alvotech's (ALVO) quarterly Cash from Investing Activities came in at -$46.2 million in Q1 2026, down 126.5% YoY from $174.3 million in Q1 2025, and down 193.0% on a QoQ basis from -$15.8 million in Q4 2025.
Alvotech (ALVO) Cash from Investing Activities (2022 - 2026) Analysis & Trends
Alvotech (ALVO) has 5 years of Cash from Investing Activities data on file, last reported at -$46.2 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 126.5% year-over-year to -$46.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$130.0 million (down 450.93% YoY) and the FY2025 annual result came in at -$104.2 million, down 452.34% from the prior year.
- Cash from Investing Activities retreated to -$46.2 million in Q1 2026, from -$15.8 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $22.8 million in Q3 2024 to a low of -$63.5 million in Q4 2022.
- A 5-year average of -$22.5 million and a median of -$18.9 million in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities jumped 74.92% — and 2025, when it tumbled 486.06%.
- Tracing ALVO's Cash from Investing Activities over 5 years: stood at -$63.5 million in 2022, then advanced by 27.07% to -$46.3 million in 2023, then soared by 59.28% to -$18.9 million in 2024, then gained by 16.44% to -$15.8 million in 2025, then plunged by 193.0% to -$46.2 million in 2026.
- The last three Cash from Investing Activities figures came in at -$46.2 million (Q1 2026), -$15.8 million (Q4 2025), and -$39.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alvotech | 1.26 Bn | 1.26 Bn | 5.09 Mn | -46.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.20 Mn |
| Mar 31, 2026 | -46.20 Mn |
| Dec 31, 2025 | -15.77 Mn |
| Dec 31, 2025 | -15.77 Mn |
| Sep 30, 2025 | -39.45 Mn |
| Sep 30, 2025 | -39.45 Mn |
| Jun 30, 2025 | -28.60 Mn |
| Jun 30, 2025 | -28.60 Mn |
| Mar 31, 2025 | -20.40 Mn |
| Mar 31, 2025 | -20.40 Mn |
| Dec 31, 2024 | -18.87 Mn |
| Dec 31, 2024 | -18.87 Mn |
| Sep 30, 2024 | 22.75 Mn |
| Sep 30, 2024 | 22.75 Mn |
| Jun 30, 2024 | -7.09 Mn |
| Jun 30, 2024 | -7.09 Mn |
| Mar 31, 2024 | -3.48 Mn |
| Mar 31, 2024 | -3.48 Mn |
| Dec 31, 2023 | -46.34 Mn |
| Dec 31, 2023 | -46.34 Mn |